SKB264 plus QL1706 for advanced cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs—SKB264 and QL1706—for women with cervical cancer that has come back or spread and is not curable with standard treatments. The goal is to see if this new combination can help shrink tumors or slow the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older.
- You have recurrent or metastatic cervical cancer (squamous cell, adenocarcinoma, or adenosquamous types) that cannot be treated with surgery or radiation.
- You have already tried at least one platinum-based chemotherapy and it either stopped working, caused too many side effects, or your cancer came back within 6 months of finishing it.
- You have at least one tumor that can be measured on a scan (like a CT or MRI).
- You are generally active and able to care for yourself (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called QL1706 for people with cervical cancer that has spread and no longer responds to PD-1/PD-L1 therapy. It may offer a new treatment option if you have tried this type of immunotherapy before.
This trial tests whether adding a new immunotherapy drug called QL1706 to standard chemotherapy before surgery can help treat early-stage cervical cancer better. The goal is to shrink tumors and improve outcomes for patients who haven't had immune therapy before.
This trial tests a new combination treatment for cervical cancer that has come back or spread. It may be an option for people who have not had previous systemic therapy for this stage of cancer.
This trial tests a combination of two drugs (sacituzumab tirumotecan and pembrolizumab) as a first maintenance treatment for cervical cancer that has spread or come back. It is for people who haven't had other cancer treatments for this stage and whose tumors have a certain protein marker (PD-L1).
This trial tests whether adding a new immunotherapy drug (QL1706) to chemotherapy before radiation treatment can help patients with advanced cervical cancer that hasn't spread to distant organs. The goal is to improve outcomes and survival.
This trial is testing whether adding the immunotherapy drug QL1706 to standard chemotherapy before surgery can improve outcomes for women with a certain type and stage of cervical cancer. It is for women whose cancer has not been treated yet and who are healthy enough for the treatment.
Hear when a new Cervical Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.